Adicet Bio to Participate in Upcoming Investor Conferences
Adicet Bio, Inc. announced that its management team will participate in two investor conferences scheduled for November 2026.
Stocks · News reference
Adicet Bio Announces Safety And Efficacy Data From Phase 1 Study Evaluating Prulacabtagene Leucel In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis; Prula-Cel Generally Well Tolerated With No CRS Greater Than Grade 2 And No IEC-HS Or ICANS
-At 12-months, 54% of evaluable patients achieved DORIS remission and 50% of patients achieved CRR--All patients discontinued immunosuppressants –- All but one patient tapered background steroids to ≤5 mg prednisone
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wedbush Maintains Outperform on Adicet Bio, Raises Price Target to $28
Wedbush analyst Robert Driscoll maintains Adicet Bio (NASDAQ:ACET) with a Outperform and raises the price target from $25 to $28.
HC Wainwright & Co. Maintains Buy on Adicet Bio, Raises Price Target to $34
HC Wainwright & Co. analyst Robert Burns maintains Adicet Bio (NASDAQ:ACET) with a Buy and raises the price target from $27 to $34.
Adicet Bio shares are trading lower after the company announced safety and efficacy data from the Phase 1 study evaluating prulacabtagene leucel as a potential treatment for patients with systemic lupus erythematosus with or without lupus nephritis.